Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | USP19 | O94966 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746602 | 0.85 | NSD2 (0.32) | RAB9ANSD2CASP6 | |
| SCHEMBL2535973 | 0.81 | EPHX1 (0.39) | SMN1; SMN2HTTUSP19 | |
| SCHEMBL1733962 | 0.78 | HSD17B2 (0.36) | ALDH1A1LMNA | |
| SCHEMBL8021420 | 0.76 | ALDH1A1 (0.38) | RAB9AALDH1A1LMNA | |
| SCHEMBL27796397 | 0.76 | ALDH1A1 (0.38) | RAB9AALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL4954787 | 0.74 | GRIN2B (0.46) | HTTLMNA | |
| SCHEMBL20825893 | 0.73 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2HTTLMNAUSP19 | |
| SCHEMBL16148375 | 0.73 | MEN1 (0.33) | RAB9AALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL2936663 | 0.73 | MEN1 (0.33) | RAB9AALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL2930360 | 0.72 | HTT (0.33) | ALDH1A1SMN1; SMN2HTTLMNAUSP19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | RAB9A 2029/4885NSD2 4705/4885CASP6 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.